AU2015300902B2 - Anti-ceramide antibodies - Google Patents

Anti-ceramide antibodies Download PDF

Info

Publication number
AU2015300902B2
AU2015300902B2 AU2015300902A AU2015300902A AU2015300902B2 AU 2015300902 B2 AU2015300902 B2 AU 2015300902B2 AU 2015300902 A AU2015300902 A AU 2015300902A AU 2015300902 A AU2015300902 A AU 2015300902A AU 2015300902 B2 AU2015300902 B2 AU 2015300902B2
Authority
AU
Australia
Prior art keywords
antibody
subject
ceramide
antigen
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015300902A
Other languages
English (en)
Other versions
AU2015300902A1 (en
Inventor
Richard Kolesnick
Jimmy Rotolo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ceramide Therapeutics
Memorial Sloan Kettering Cancer Center
Original Assignee
Ceram Therapeutics
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ceram Therapeutics, Memorial Sloan Kettering Cancer Center filed Critical Ceram Therapeutics
Publication of AU2015300902A1 publication Critical patent/AU2015300902A1/en
Application granted granted Critical
Publication of AU2015300902B2 publication Critical patent/AU2015300902B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2015300902A 2014-08-07 2015-08-07 Anti-ceramide antibodies Active AU2015300902B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462034453P 2014-08-07 2014-08-07
US62/034,453 2014-08-07
PCT/US2015/044144 WO2016022883A1 (en) 2014-08-07 2015-08-07 Anti-ceramide antibodies

Publications (2)

Publication Number Publication Date
AU2015300902A1 AU2015300902A1 (en) 2017-03-02
AU2015300902B2 true AU2015300902B2 (en) 2020-05-28

Family

ID=55264608

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015300902A Active AU2015300902B2 (en) 2014-08-07 2015-08-07 Anti-ceramide antibodies

Country Status (12)

Country Link
US (4) US10450385B2 (enExample)
EP (1) EP3177650B1 (enExample)
JP (1) JP6670297B2 (enExample)
KR (1) KR102296416B1 (enExample)
CN (1) CN107074949B (enExample)
AU (1) AU2015300902B2 (enExample)
CA (1) CA2957415C (enExample)
IL (1) IL250374B (enExample)
MX (1) MX391141B (enExample)
RU (1) RU2717651C2 (enExample)
SG (1) SG11201700787XA (enExample)
WO (1) WO2016022883A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI752012B (zh) 2016-03-04 2022-01-11 美商Ｊｎ生物科學有限責任公司 針對tigit之抗體
EP3559043A4 (en) 2016-12-23 2020-08-05 Bluefin Biomedicine, Inc. ANTI-SEZ6L2 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES
US20200362057A1 (en) 2019-05-16 2020-11-19 Snake River Bioscience, Inc. Compositions and methods for the treatment of major depressive disorder
NZ783695A (en) * 2019-06-06 2025-08-29 Jacobio Pharmaceuticals Co Ltd Binding molecule specific for cd73 and use of binding molecule
US10975169B1 (en) * 2019-09-27 2021-04-13 Memorial Sloan Kettering Cancer Center Methods for treating diabetic retinopathy using anti-ceramide monoclonal antibody 2A2
KR102245082B1 (ko) * 2020-02-14 2021-04-26 단국대학교 천안캠퍼스 산학협력단 치주인대전구세포 표면에 특이적으로 결합하는 두 가지 IgG 타입 단일클론항체 LG43, LG73 및 그의 용도
IL296550A (en) * 2020-03-18 2022-11-01 Memorial Sloan Kettering Cancer Center Anti-ceramide antibodies
CR20220611A (es) 2020-06-02 2023-06-07 Arcus Biosciences Inc Anticuerpos anti-tigit
KR20230162788A (ko) * 2021-03-16 2023-11-28 메모리얼 슬로안 케터링 캔서 센터 항-세라마이드 항체를 이용한 상처 치유 증진
WO2024226646A2 (en) * 2023-04-25 2024-10-31 Memorial Sloan-Kettering Cancer Center Dlk1 -targeting antibodies and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008137901A2 (en) * 2007-05-06 2008-11-13 Sloan Kettering Institute For Cancer Research Methods for treating and preventing gi syndrome and graft versus host disease
US20100034814A1 (en) * 2007-05-30 2010-02-11 Sabbadini Roger A Compositions and methods for binding lysophosphatidic acid
WO2013177596A2 (en) * 2012-05-25 2013-11-28 Sloan Kettering Institute For Cancer Methods for treating gi syndrome and graft versus host disease

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
JPH02128697A (ja) * 1988-11-09 1990-05-17 Hoechst Japan Ltd 抗フコシルセラミドモノクローナル抗体
US7897753B2 (en) 2002-02-20 2011-03-01 Sirna Therapeutics, Inc. RNA interference mediated inhibition of XIAP gene expression using short interfering nucleic acid (siNA)
RU2310393C1 (ru) 2006-02-16 2007-11-20 ФГУ Научно-исследовательский институт по изучению лепры Федерального агентства по здравоохранению и социальному развитию Российской Федерации Способ прогнозирования обострений лепрозных невропатий у больных лепрой
US8410251B2 (en) * 2008-06-20 2013-04-02 National University Corporation Okayama University Antibody against calcified globule and use of the same
KR101050829B1 (ko) * 2008-10-02 2011-07-20 서울대학교산학협력단 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제
US9090679B2 (en) * 2009-04-17 2015-07-28 Immunas Pharma, Inc. Antibodies that specifically bind to A beta oligomers and use thereof
FR2971250A1 (fr) * 2011-02-07 2012-08-10 Univ Nantes Anticorps anti-gb3 utiles dans le traitement des maladies associees a l'angiogenese
KR101256351B1 (ko) 2011-11-22 2013-04-19 김석진 필터 삽입공을 갖는 카메라 후드
PL2818483T3 (pl) * 2012-02-21 2018-01-31 Toray Industries Kompozycja lecznicza do leczenia i/lub zapobiegania nowotworowi
IL296550A (en) * 2020-03-18 2022-11-01 Memorial Sloan Kettering Cancer Center Anti-ceramide antibodies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008137901A2 (en) * 2007-05-06 2008-11-13 Sloan Kettering Institute For Cancer Research Methods for treating and preventing gi syndrome and graft versus host disease
US20100034814A1 (en) * 2007-05-30 2010-02-11 Sabbadini Roger A Compositions and methods for binding lysophosphatidic acid
WO2013177596A2 (en) * 2012-05-25 2013-11-28 Sloan Kettering Institute For Cancer Methods for treating gi syndrome and graft versus host disease

Also Published As

Publication number Publication date
EP3177650A4 (en) 2018-01-03
US11447572B2 (en) 2022-09-20
RU2017105596A3 (enExample) 2019-04-17
US20190389970A1 (en) 2019-12-26
AU2015300902A1 (en) 2017-03-02
EP3177650B1 (en) 2025-11-05
US20230416409A1 (en) 2023-12-28
RU2017105596A (ru) 2018-09-07
EP3177650A1 (en) 2017-06-14
WO2016022883A1 (en) 2016-02-11
CN107074949B (zh) 2021-06-15
BR112017002433A2 (pt) 2017-11-28
CA2957415A1 (en) 2016-02-11
US10450385B2 (en) 2019-10-22
SG11201700787XA (en) 2017-02-27
CN107074949A (zh) 2017-08-18
NZ728981A (en) 2024-03-22
MX391141B (es) 2025-03-21
US20170335014A1 (en) 2017-11-23
MX2017001686A (es) 2017-09-01
JP2017527544A (ja) 2017-09-21
US20250197524A1 (en) 2025-06-19
IL250374B (en) 2021-04-29
IL250374A0 (en) 2017-03-30
KR102296416B1 (ko) 2021-09-01
KR20170066327A (ko) 2017-06-14
RU2717651C2 (ru) 2020-03-24
CA2957415C (en) 2021-07-13
JP6670297B2 (ja) 2020-03-18

Similar Documents

Publication Publication Date Title
US20250197524A1 (en) Anti-ceramide antibodies
US20250145699A1 (en) Antibody-based therapy of transthyretin (ttr) amyloidosis and human-derived antibodies therefor
US10501555B2 (en) Humanized anti-trop-2 monoclonal antibodies and uses thereof
TWI801862B (zh) 抗ｔｉｇｉｔ的抗體、其製備方法和應用
AU2021330879B2 (en) Development of drug therapeutic agent containing adaptor and use thereof
CN107847593A (zh) 治疗抗体及其用途
WO2022143550A1 (zh) 间皮素结合分子及其应用
US8470325B2 (en) Method of treating amykloidosis comprising administering an anti-HMGB-1 antibody
US20220242944A1 (en) Antigen binding molecules that bind pdgf-b and pdgf-d and uses thereof
CN114685667A (zh) 间皮素结合分子及其应用
EP4253424A1 (en) Bispecific antibody and use thereof
BR112017002433B1 (pt) Anticorpos anticeramida
CA2968330C (en) Humanized anti-trop-2 monoclonal antibodies and uses thereof
CN117285628A (zh) 抗vista抗体及其应用
CA3203732A1 (en) Anti-survivin antibodies for treatment of autoimmune diseases

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)